IL-36 signaling as a drug target in Crohn's disease patients with IL36RN mutations.
Saved in:
| Title: | IL-36 signaling as a drug target in Crohn's disease patients with IL36RN mutations. |
|---|---|
| Authors: | Hecker J; Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Campus Benjamin Franklin, Berlin, Germany., Plattner C; Biocenter, Institute of Bioinformatics, Medical University of Innsbruck, Innsbruck, Austria., Cancino CA; Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Campus Benjamin Franklin, Berlin, Germany.; Deutsches Rheuma-Forschungszentrum, ein Institut der Leibniz-Gemeinschaft, Berlin, Germany., Löscher BS; Institute of Clinical Molecular Biology, Kiel University and University Medical Center, Kiel, Germany., Saurenbach J; Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Campus Benjamin Franklin, Berlin, Germany., Letizia M; Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Campus Benjamin Franklin, Berlin, Germany., Rieder D; Biocenter, Institute of Bioinformatics, Medical University of Innsbruck, Innsbruck, Austria., Freise I; Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Campus Benjamin Franklin, Berlin, Germany., Koop K; Department of Medicine 1, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany., Neufert C; Department of Medicine 1, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany., Kunkel D; Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Flow & Mass Cytometry Core Facility, Berlin, Germany., Al Khatim Z; Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Campus Benjamin Franklin, Berlin, Germany., Schaafs LA; Department of Radiology, Charité - Universitätsmedizin Berlin, Berlin, Germany., Schütz A; Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany., Becker C; Department of Medicine 1, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany., Atreya R; Department of Medicine 1, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany., Trajanoski Z; Biocenter, Institute of Bioinformatics, Medical University of Innsbruck, Innsbruck, Austria., Franke A; Institute of Clinical Molecular Biology, Kiel University and University Medical Center, Kiel, Germany., Sonnenberg E; Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Campus Benjamin Franklin, Berlin, Germany., Hegazy AN; Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Campus Benjamin Franklin, Berlin, Germany.; Deutsches Rheuma-Forschungszentrum, ein Institut der Leibniz-Gemeinschaft, Berlin, Germany., Siegmund B; Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Campus Benjamin Franklin, Berlin, Germany. britta.siegmund@charite.de., Weidinger C; Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Campus Benjamin Franklin, Berlin, Germany. carl.weidinger@charite.de. |
| Corporate Authors: | TRR241 IBDome Consortium |
| Source: | EMBO molecular medicine [EMBO Mol Med] 2025 Jul; Vol. 17 (7), pp. 1539-1555. Date of Electronic Publication: 2025 May 30. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: EMBO Press Country of Publication: Germany NLM ID: 101487380 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1757-4684 (Electronic) Linking ISSN: 17574676 NLM ISO Abbreviation: EMBO Mol Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1757-4684 |
|---|---|
| DOI: | 10.1038/s44321-025-00245-z |
